Charles River Dives Deep Into Cell and Gene Therapy With Cognate BioServices Acquisition

Charles River Laboratories will acquire Cognate BioServices, a cell and gene therapy contract development and manufacturing organization, in an $875 million cash deal that will significantly expand the company’s capabilities in the high-growth cell and gene therapy sector.